CO36 Network Meta-Analysis (NMA) to Assess Comparative Efficacy of Lenvatinib Plus Pembrolizumab Compared with Other First-Line Treatments for Management of Advanced Renal Cell Carcinoma (ARCC)
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.134
https://www.valueinhealthjournal.com/article/S1098-3015(22)00335-7/fulltext
Title :
CO36 Network Meta-Analysis (NMA) to Assess Comparative Efficacy of Lenvatinib Plus Pembrolizumab Compared with Other First-Line Treatments for Management of Advanced Renal Cell Carcinoma (ARCC)
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00335-7&doi=10.1016/j.jval.2022.04.134
First page :
Section Title :
Open access? :
No
Section Order :
10110